Frontiers in Immunology (Jun 2019)
Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus
- Bárbara Soria-Juan,
- Natalia Escacena,
- Vivian Capilla-González,
- Yolanda Aguilera,
- Lucía Llanos,
- Juan R. Tejedo,
- Juan R. Tejedo,
- Francisco J. Bedoya,
- Francisco J. Bedoya,
- Verónica Juan,
- Antonio De la Cuesta,
- Rafael Ruiz-Salmerón,
- Enrique Andreu,
- Lukas Grochowicz,
- Felipe Prósper,
- Fermín Sánchez-Guijo,
- Francisco S. Lozano,
- Manuel Miralles,
- Lourdes Del Río-Solá,
- Gregorio Castellanos,
- José M. Moraleda,
- Robert Sackstein,
- Mariano García-Arranz,
- Damián García-Olmo,
- Franz Martín,
- Franz Martín,
- Abdelkrim Hmadcha,
- Abdelkrim Hmadcha,
- Bernat Soria,
- Bernat Soria,
- Bernat Soria,
- Collaborative Working Group “Noma Project Team”
Affiliations
- Bárbara Soria-Juan
- Fundación Jiménez Díaz Health Research Institute, Madrid, Spain
- Natalia Escacena
- Department of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain
- Vivian Capilla-González
- Department of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain
- Yolanda Aguilera
- Department of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain
- Lucía Llanos
- Fundación Jiménez Díaz Health Research Institute, Madrid, Spain
- Juan R. Tejedo
- Department of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain
- Juan R. Tejedo
- Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain
- Francisco J. Bedoya
- Department of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain
- Francisco J. Bedoya
- Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain
- Verónica Juan
- Andalusian eHealth Library, Sevilla, Spain
- Antonio De la Cuesta
- Unidad de Isquemia Crónica de Miembros Inferiores, Hospital Victoria Eugenia de la Cruz Roja, Sevilla, Spain
- Rafael Ruiz-Salmerón
- Servicio de Cardiología, Hospital Universitario Virgen Macarena, Sevilla, Spain
- Enrique Andreu
- Clínica Universidad de Navarra, Pamplona, Spain
- Lukas Grochowicz
- Clínica Universidad de Navarra, Pamplona, Spain
- Felipe Prósper
- Clínica Universidad de Navarra, Pamplona, Spain
- Fermín Sánchez-Guijo
- IBSAL-Hospital Universitario Salamanca, Salamanca, Spain
- Francisco S. Lozano
- IBSAL-Hospital Universitario Salamanca, Salamanca, Spain
- Manuel Miralles
- Department of Surgery, University of Valencia, Valencia, Spain
- Lourdes Del Río-Solá
- 0Cirugía Vascular, Hospital Universitario de Valladolid, Valladolid, Spain
- Gregorio Castellanos
- 1Servicio Hematología y Hemoterapia, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
- José M. Moraleda
- 1Servicio Hematología y Hemoterapia, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
- Robert Sackstein
- 2Herbert Wertheim College of Medicine, Florida International University, Miami, FL, United States
- Mariano García-Arranz
- Fundación Jiménez Díaz Health Research Institute, Madrid, Spain
- Damián García-Olmo
- Fundación Jiménez Díaz Health Research Institute, Madrid, Spain
- Franz Martín
- Department of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain
- Franz Martín
- Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain
- Abdelkrim Hmadcha
- Department of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain
- Abdelkrim Hmadcha
- Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain
- Bernat Soria
- Department of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain
- Bernat Soria
- Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain
- Bernat Soria
- 3ISABIAL and Institute of Bioengineering, University Miguel Hernández de Elche, Alicante, Spain
- Collaborative Working Group “Noma Project Team”
- DOI
- https://doi.org/10.3389/fimmu.2019.01151
- Journal volume & issue
-
Vol. 10
Abstract
Cell therapy is a progressively growing field that is rapidly moving from preclinical model development to clinical application. Outcomes obtained from clinical trials reveal the therapeutic potential of stem cell-based therapy to deal with unmet medical treatment needs for several disorders with no therapeutic options. Among adult stem cells, mesenchymal stem cells (MSCs) are the leading cell type used in advanced therapies for the treatment of autoimmune, inflammatory and vascular diseases. To date, the safety and feasibility of autologous MSC-based therapy has been established; however, their indiscriminate use has resulted in mixed outcomes in preclinical and clinical studies. While MSCs derived from diverse tissues share common properties depending on the type of clinical application, they markedly differ within clinical trials in terms of efficacy, resulting in many unanswered questions regarding the application of MSCs. Additionally, our experience in clinical trials related to critical limb ischemia pathology (CLI) shows that the therapeutic efficacy of these cells in different animal models has only been partially reproduced in humans through clinical trials. Therefore, it is crucial to develop new research to identify pitfalls, to optimize procedures and to clarify the repair mechanisms used by these cells, as well as to be able to offer a next generation of stem cell that can be routinely used in a cost-effective and safe manner in stem cell-based therapies targeting CLI.
Keywords
- cellular medicaments
- cell-based therapy
- clinical trials
- diabetes
- critical limb ischemia
- cost-effective
